Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ustekinumab Biosimilar (Cipla Australia Pty Ltd.), 乌司奴单抗生物类似药(Cipla Australia Pty Ltd.), UTEKNIX |
Target |
Action inhibitors |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Australia (11 Feb 2025), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arthritis, Psoriatic | Australia | 11 Feb 2025 | |
Plaque psoriasis | Australia | 11 Feb 2025 |